Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Neuroscience > Neuroscience Week 4: AntiParkinsons meds > Flashcards

Neuroscience Week 4: AntiParkinsons meds Flashcards

1
Q

Cardinal motor signs of Parkinson’s Disease

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Drug classes to treat Parkinson’s disease

5 listed

A
  • Dopamine Precursors (L-DOPA Carbidopa (Sinemet)
  • Dopamine Agonists (Ropinirole, Pramipexole)
  • MAO inhibitors (Selegiline)
  • COMT Inhibitors (Entacapone)
  • Muscarinic antagonists (trihexyphenidyl)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

MOA of Drug classes to treat Parkinson’s disease

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Dopaminergic nerve terminal

A
  • left-hand presynaptic bouton with dopamine vesicles
  • right-hand side postsynaptic neurons within the striatum
  • dopamine is produced from the precursor tyrosine by tyrosine hydroxylase to L-DOPA then to Dopamine by aromatic amino acid decarboxylase (dopa carboxylase)
  • dopamine is then transported to the presynaptic terminal and released upon activation of the nerve terminal into the synaptic cleft where it binds the postsynaptic dopamine receptors within the striatum
  • dopamine is removed from the synaptic cleft and reuptake by dopamine transporter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

L-DOPA structure

A

mainstay for treating Parkinsons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

dopamine is produced from the

A

precursor tyrosine by tyrosine hydroxylase to L-DOPA then to Dopamine by aromatic amino acid decarboxylase (dopa carboxylase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Dopamine cross the blood brain barrier?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

L-DOPA cross the blood brain barrier?

A

Yes

Levodopa does cross and is transported across and reaches the brain is taken up by dopamine transporter at nerve terminals and is converted by amino acid decarboxylase (dopa carboxylase) to dopamine bypassing the rate-limiting step of tyrosine to L-Dopa by tyrosine hydroxylase within singular nerves increasing dopamine production on a per neuron basis

L dopa is transported across BBB by neutral amino acid transporter where it is converted to dopamine by central dopa decarboxylase

L DOPA can be converted in PNS by peripheral dopa carboxylase which is present in many peripheral tissues

to increase bioavailability of L-DOPA in the CNS it is administered to gethetr with a peripheral dopa carboxylase inhibitor (Carbidopa)

Carbidopa does not cross BBB and can only inhibit PDC (peripheral dopa carboxylase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Carbidopa

A

L dopa is transported across BBB by neutral amino acid transporter where it is converted to dopamine by central dopa decarboxylase

L DOPA can be converted in PNS by peripheral dopa carboxylase which is present in many peripheral tissues

to increase bioavailability of L-DOPA in the CNS it is administered to gethetr with a peripheral dopa carboxylase inhibitor (Carbidopa)

Carbidopa does not cross BBB and can only inhibit PDC (peripheral dopa carboxylase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

peripheral dopa carboxylase inhibitor

A

Carbidopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sinemet

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Carbidopa structure & effects

3 listed

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Major side effects of L-Dopa or sinemet

A
  1. GASTROINTESTINAL: Nausea is thought to be due to stimulation of dopamine receptors (D2) in the emetic center of the brain (area postrema) where BBB does not exist. Usually subsides with time. Can be treated with domperidone, a D2 antagonist that does not cross BBB, but this is risky in PD patient.
  2. CARDIOVASCULAR: Side effects include tachychardia, atrial fibrillation due to sympathomimetic action of L-dopa, also a precursor to norepinephrine.
  3. PSYCHOSIS: Nightmares or hallucinations may occur due to stimulation of dopamine receptors in frontal cortex.
  4. DYSKINESIA: Long-term treatment with L-dopa may eventually lead to L-dopa-induced dyskinesiasby unknown mechanism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

D2 antagonist used to treat GI symptoms of Sinemet

A

Domperidone

a D2 antagonist that does not cross BBB, but this is risky in PD patient.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Sinemet GI Side Effects

A

GASTROINTESTINAL: Nausea is thought to be due to stimulation of dopamine receptors (D2) in the emetic center of the brain such as in the (area postrema) where BBB does not exist. Usually subsides with time. Can be treated with domperidone, a D2 antagonist that does not cross BBB, but this is risky in PD patient.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Sinemet Cardiovascular Side effects

A

CARDIOVASCULAR: Side effects include tachychardia, atrial fibrillation due to sympathomimetic action of L-dopa, which is also a precursor to norepinephrine.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Sinemet Psychosis Side Effects

A

PSYCHOSIS: Nightmares or hallucinations may occur due to stimulation of dopamine receptors in frontal cortex.

overstimulation of dopamine receptors in the frontal cortex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Sinemet Side Effects Dyskinesia

A

DYSKINESIA: Long-term treatment with L-dopa may eventually lead to L-dopa-induced dyskinesias by unknown mechanism

Major side effect with long-term use results in unwanted movements such as chorea seen in Huntington’s Disease, Etiology is idiopathic

19
Q

L-DOPA Pharmacokinetics: Absorption

A

GI Absorption by LNAA transport

20
Q

L-DOPA Pharmacokinetics: Time to Peak Plasma Concentration

A

.5 - 2.0 hours

21
Q

L-DOPA Pharmacokinetics: Plasma half-life

A

1 - 3 hours

22
Q

L-DOPA Pharmacokinetics: Duration of action

A

4.0 - 6.0 hours

23
Q

L-DOPA Pharmacokinetics: Caveat

A

In early stages of PD, the duration of action of L-dopa is longer than plasma half-life because L-dopa is taken up by dopaminergic nerve terminals in striatum, and released as needed. As nigralneurons degenerate, the duration of action becomes shortened. There is less “buffering capacity” of L-dopa as DA neurons are increasingly lost during progressive neuronal degeneration.

24
Q

L-Dopa Taken with Food

A

Typically not taken with a protein meal because protein can compete with L-DOPA for uptake with Amino Acid Transport system

25
Q

Contraindication of L-Dopa (Sinemet)

A
  • psychotic because of the propensity of L-DOPA to cause hallucinations and nightmares psychotic symptoms
  • Also, monitor closely in patients with cardiovascular disease
26
Q

Limitations of long term use of L-Dopa

A
  • “wearing off” phenomenon - diminshment of duration of action, increasing dose and frequency of dose can often lead to dyskinesias
  • Dyskinesia - excessive abnormal and involuntary movements
27
Q

COMT Inhibitors

A

Catecholo-O-Methyltransferase Inhibitors to further enhance L-Dopa bioavailability

Entacapone

28
Q

Entacapone MOA

A

inhibits degradation of L-Dopa to 3-O-methyldopa mediated by Catecholo-O-Methyltransferase

29
Q

Carbidopa, Levodopa, Entacapone Combination and properties

5 listed

A

Stalevo

30
Q

Monamine Oxidase-B Inhibitors MOA

A

can be used as adjunct therapy w/ Senemet or monotherapy

inhibits Monamine Oxidase-B degradation pathway which converts Dopamine to DOPAC metabolite

31
Q

Selegilene and properties

A
  • Monamine Oxidase-B inhibitor
  • retards catabolism of dopamine in CNS
  • used in early PD stages prior to L-dopa or as an adjunct
  • prevents dopamine degradation to DOPAC
32
Q

Dopamine Receptor Agonists MOA

A

bypass presynaptic terminal altogether and MOA is to directly stimulate postsynaptic Dopamine receptors in striatal cells

33
Q

Dopamine Receptor Agonists Advantages

4 listed

A
34
Q

Dopamine Receptor Agonists Disadvantage

A

Not as effective as L-Dopa for alleviating motor symptoms of Parkinson’s disease

35
Q

Ropinirole (Requip) MOA

A

D2 Receptor Agonist

36
Q

Ropinirole (Requip) Side Effects

A
  • Nausea
  • Orthostatic Hypotension
  • Hallucinations
37
Q

D2 Receptor Agonist

A

Ropinirole (Requip)

38
Q

Muscarinic receptor Antagonists MOA

A

a small population of cholinergic interneurons in the striatum acetylcholine released by these neurons act on muscarinic receptors in postsynaptic striatal nuerons and is thought to antagonize dopaminergic stimulation within the striatum

39
Q

Benztropine and Trihexyphenidyl MOA

A

thought to restore Ach:Dopamine balance in the corpus striatum

40
Q

Benzotropine and Trihexyphenidyl Advantages

A

modest antiparkinson action

41
Q

Benzotropine and Trihexyphenidyl disadvantages

A

Have parasympathetic side effects

42
Q

Benzotropine and Trihexyphenidyl Use

A

treat tremor with little effect on bradykinesia

43
Q

Antiparkinson and other movement disorders Drug Summary

A

Katsung chapter 28

44
Q

Combination pill of L-DOPA and Carbidopa

A

Sinemet

Neuroscience (96 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions